Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice

References

• Kotzin BL. Systemic lupus erythematosus. Cell. 1996; 85:303–306.
   PubMed Web of Science ®Google Scholar
• Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol. 2003; 24:595–602.
   PubMed Web of Science ®Google Scholar
• James J, Harley J, Scofield R. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol. 2006; 18:462–467.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2:675–680.
   PubMed Web of Science ®Google Scholar
• Lenert P. Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther. 2006; 8:203.
   PubMedGoogle Scholar
• Cook D, Pisetsky D, Schwartz D. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004; 5:975–979.
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway C. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998; 2:253–258.
   PubMed Web of Science ®Google Scholar
• Schnare M, Barton G, Holt A, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001; 2:947–950.
   PubMed Web of Science ®Google Scholar
• Deane J, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol. 2006; 177:6573–6578.
   Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408:740–745.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002; 416:603–607.
   PubMed Web of Science ®Google Scholar
• Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003; 19:837–847.
   PubMed Web of Science ®Google Scholar
• Christensen C, Kashgarian M, Alexopoulou L, Flavell R, Akira S, Shlomchik M. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005; 202:321–331.
   PubMed Web of Science ®Google Scholar
• Ho P, Fontoura P, Ruiz P, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003; 171:4920–4926.
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Platten M, Sobel RA, DeVoss JJ, Lee LY, Kidd BA, Tomooka BH, Capers J, Agrawal A, Gupta R, Zernik J, Yee MK, Lee BJ, Garren H, Robinson WH, Steinman L. A Suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol. 2005; 175:6226–6234.
   PubMed Web of Science ®Google Scholar
• Jacob C, Van Der Meide P, McDevitt H. In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma-interferon. J Exp Med. 1987; 166:798–803.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol. 1997; 158:1466–1472.
   PubMed Web of Science ®Google Scholar
• Peng S, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest. 1997; 99:1936–1946.
   PubMed Web of Science ®Google Scholar
• Balomenos D, Rumold R, Theofilopoulos A. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest. 1998; 101:364–371.
   PubMed Web of Science ®Google Scholar
• Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997; 186:1623–1631.
   PubMed Web of Science ®Google Scholar
• Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JW. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int. 1984; 25:689–695.
   PubMed Web of Science ®Google Scholar
• Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med. 1978; 148:1198–1215.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Seaman W. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985; 161:378–391.
   PubMed Web of Science ®Google Scholar
• Connolly K, Roubinian J, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+T cells is required to suppress autoimmunity. J Immunol. 1992; 149:3083–3088.
   PubMedGoogle Scholar
• Richards H, Satoh M, Jennette J, Croker B, Yoshida H, Reeves W. Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 2001; 60:2173–2180.
   Google Scholar
• Santiago M-L, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med. 1997; 185:65–70.
   PubMed Web of Science ®Google Scholar
• Graham K, Vaysberg M, Kuo A, Utz P. Autoantigen arrays for multiplex analysis of antibody isotypes. Proteomics. 2006; 6:5720–5724.
   PubMed Web of Science ®Google Scholar
• Stein C, Subasinghe C, Sinozuka K, Coehn J. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucl Acids Res. 1988; 16:3209–3221.
   PubMed Web of Science ®Google Scholar
• Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods. 1986; 13:97–102.
   PubMedGoogle Scholar
• Christensen C, Shupe J, Nickerson K, Kashgarian M, Flavell R, Shlomchik M. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25:417–428.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA. 1996; 93:2879–2883.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005; 202:1131–1139.
   PubMed Web of Science ®Google Scholar
• Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005; 202:1575–1585.
   PubMed Web of Science ®Google Scholar
• Savarese E, Chae O-W, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood. 2006; 107:3229–3234.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR. Murine dendritic cell type I IFN production induced by human igg-rna immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol. 2007; 178:6876–6885.
   PubMed Web of Science ®Google Scholar
• Patole PS, Grone H-J, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlondorff D, Anders H-J. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol. 2005; 16:1326–1338.
   PubMed Web of Science ®Google Scholar
• Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52:1491–1503.
   PubMed Web of Science ®Google Scholar
• Berland R, Fernandez L, Kari E, Han J, Lomakin I, Akira S, Wortis H, Kearney J, Ucci A, Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity. 2006; 25:429–440.
   PubMed Web of Science ®Google Scholar
• Lau C, Broughton C, Tabor A, Akira S, Flavell R, Mamula M, Christensen S, Shlomchik M, Biglianti G, Rifkin I, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005; 202:1171–1177.
   PubMed Web of Science ®Google Scholar
• Diebold S, Kaisho T, Hemmi H, Akira S, Sousa CE. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004; 303:1529–1531.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science. 2004; 303:1526–1529.
   PubMed Web of Science ®Google Scholar
• Lund J, Alexopoulou L, Sato A, Karow M, Adams N, Gale N, Iwasaki A, Flavell R. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA. 2004; 101:5598–5603.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002; 3:196–200.
   PubMed Web of Science ®Google Scholar
• Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: Gene structure, expression, and evolution. Eur Cytokine Netw. 2000; 11:362–371.
   PubMed Web of Science ®Google Scholar
• Chuang T, Ulevitch R. Cloning and characterization of a sub-family of human toll-like receptors hTLR-7, hTLR-8, and hTLR-9. Eur Cytokine Netw. 2000; 11:372–378.
   PubMed Web of Science ®Google Scholar
• Pisitkun P, Deane J, Difilippantonio M, Tarasenko T, Saterthwaite A, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006; 312:1669–1672.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, Liang C, Bartov G, McDaniel LD, Zhou ZJ, Schultz RA, Wakeland EK. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA. 2006; 103:9970–9975.
   PubMed Web of Science ®Google Scholar
• Dong L, Ito S, Ishii K, Klinman D. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheumat. 2005; 52:651–658.
   PubMed Web of Science ®Google Scholar
• Patole PS, Zecher D, Pawar RD, Grone H-J, Schlondorff D, Anders H-J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol. 2005; 16:3273–3280.
   PubMed Web of Science ®Google Scholar
• Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders H-J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007; 18:1721–1731.
   PubMed Web of Science ®Google Scholar
• Krieg A, Vollmer J. Toll-like receptors 7, 8, and 9: Linking innate immunity to autoimmunity. Immunol Rev. 2007; 220:251–269.
   PubMed Web of Science ®Google Scholar